Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

New Camera Enables High Resolution Video Recording at Ultrahigh Speeds

By BiotechDaily International staff writers
Posted on 07 May 2013
Print article
Image: Shimadzu’s Hyper Vision HPV-X high-speed video camera (Photo courtesy of Shimadzu).
Image: Shimadzu’s Hyper Vision HPV-X high-speed video camera (Photo courtesy of Shimadzu).
A new video camera has been developed with specialized sensor technology that enables the achievement of record ultrahigh-speed continuous recording of high-resolution images.

High-speed video technology has been used as an important analysis tool in a variety of fields including microbiological and other microscopic phenomena, materials failure, explosions, and electric discharge. Shimadzu (Nakagyo-ku; Kyoto, Japan) now introduces the Hyper Vision HPV-X video camera, which allows observation of previously unobservable ultrahigh-speed phenomena with high temporal resolution. The camera is applicable to a broad range of fields requiring high-speed video, such as research in advanced science, engineering and medicine, space technology development, product development, and identification of causes of defects.

The HPV-X offers a choice of two modes of image resolution: “full pixel” (FP) for 100,000 pixel images and “half pixel” (HP) for 50,000 pixel images. It is also equipped with a newly developed proprietary high-speed FT-CMOS image sensor and has achieved ultrahigh-speed continuous recording at 10 million frames/second, a world's first, opening new doorways to high-speed recording. This feature is included in all Shimadzu’s Hyper Vision high-speed video cameras, but is not available from any other manufacturer. The HPV-X can record 5 million 100,000 pixel images per second (in FP mode) or 10 million 50,000 pixel images per second (in HP mode).

Recording storage capacity has been increased by increasing memory capacity and the higher frame capacity allows longer recording times. In FP resolution mode, the HPV-X can record 128 frames, which is 20% more than the previous HPV-2 model. In the HP mode, a double-memory function enables recording 256 consecutive frames for recording even longer periods. This gives the user the choice to prioritize either resolution or recording time. Near instantaneous phenomena can now be captured in even more detail: with conventional high-speed video cameras, the resolution drops as recording speed is increased, whereas with the HPV-X, recording can be performed at the maximum resolution of 400 × 250 pixels (in FP mode) regardless of the recording speed used, enabling detailed analysis of ultrahigh-speed phenomena.

Just like the previous model, the simple system configuration offers a compact and highly portable design that makes on-site setup especially simple. The HPV-X camera head just has to be connected to a laptop computer by cable. The camera also retains the same HPV software that has been so popular with users of the previous model, with intuitive features and easy-to-understand setting screens.

Related Links:
Shimadzu



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.